表紙
市場調査レポート

風疹:パイプライン製品の分析

Rubella - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 271825
出版日 ページ情報 英文 45 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
風疹:パイプライン製品の分析 Rubella - Pipeline Review, H1 2016
出版日: 2016年05月11日 ページ情報: 英文 45 Pages
概要

風疹は、三日ばしかとしても知られる、急性の接触伝染性ウイルス感染症です。風疹ウイルスは、感染者のくしゃみや咳の飛沫によって伝染します。発熱、頭痛、鼻づまりや鼻水、炎症、眼の充血、関節痛、頭蓋底・頸背部・耳介後部のリンパ節腫大などの症状があります。

当レポートでは、風疹に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

風疹の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

風疹:企業で開発中の治療薬

風疹:大学/機関で研究中の治療薬

風疹:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

風疹:企業で開発中の製品

風疹:大学/機関で研究中の製品

風疹の治療薬開発に従事している企業

  • Beijing Minhai Biotechnology Co., Ltd
  • Beijing Tiantan Biological Products Co., Ltd.
  • Biological E. Limited
  • China National Pharmaceutical Group Corporation
  • 第一三共
  • GlaxoSmithKline Plc
  • Prometheon Pharma, LLC
  • Sinovac Biotech Ltd.
  • Zydus Cadila Healthcare Limited

風疹:治療薬の評価

  • 単剤製品
  • 併用製品
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

風疹:最近のパイプライン動向

風疹:休止中のプロジェクト

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8053IDB

Summary

Global Markets Direct's, 'Rubella - Pipeline Review, H1 2016', provides an overview of the Rubella pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Rubella, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rubella and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Rubella
  • The report reviews pipeline therapeutics for Rubella by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Rubella therapeutics and enlists all their major and minor projects
  • The report assesses Rubella therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Rubella

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Rubella
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Rubella pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Rubella Overview
  • Therapeutics Development
    • Pipeline Products for Rubella - Overview
    • Pipeline Products for Rubella - Comparative Analysis
  • Rubella - Therapeutics under Development by Companies
  • Rubella - Therapeutics under Investigation by Universities/Institutes
  • Rubella - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Rubella - Products under Development by Companies
  • Rubella - Products under Investigation by Universities/Institutes
  • Rubella - Companies Involved in Therapeutics Development
    • Beijing Minhai Biotechnology Co., Ltd
    • Beijing Tiantan Biological Products Co., Ltd.
    • Biological E. Limited
    • China National Pharmaceutical Group Corporation
    • Daiichi Sankyo Company, Limited
    • GlaxoSmithKline Plc
    • Prometheon Pharma, LLC
    • Sinovac Biotech Ltd.
    • Zydus Cadila Healthcare Limited
  • Rubella - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (measles + mumps + rubella + varicella) (tetravalent) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (measles + mumps + rubella + varicella) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (measles + mumps + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (measles + mumps + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (measles + mumps + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (measles + rubella + varicella) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (measles + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (measles + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • measles + mumps + rubella + varicella vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VN-0102 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Rubella - Recent Pipeline Updates
  • Rubella - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Rubella, H1 2016
  • Number of Products under Development for Rubella - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Rubella - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016
  • Rubella - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H1 2016
  • Rubella - Pipeline by Biological E. Limited, H1 2016
  • Rubella - Pipeline by China National Pharmaceutical Group Corporation, H1 2016
  • Rubella - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Rubella - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Rubella - Pipeline by Prometheon Pharma, LLC, H1 2016
  • Rubella - Pipeline by Sinovac Biotech Ltd., H1 2016
  • Rubella - Pipeline by Zydus Cadila Healthcare Limited, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Rubella Therapeutics - Recent Pipeline Updates, H1 2016
  • Rubella - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Rubella, H1 2016
  • Number of Products under Development for Rubella - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top